[{"address1": "5980 Horton Street", "address2": "Suite 600", "city": "Emeryville", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 250 7800", "website": "https://www.omniab.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.", "fullTimeEmployees": 106, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew W. Foehr", "age": 50, "title": "President, CEO & Director", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 965849, "exercisedValue": 0, "unexercisedValue": 450384}, {"maxAge": 1, "name": "Mr. Kurt A. Gustafson", "age": 55, "title": "Executive VP of Finance & CFO", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 669222, "exercisedValue": 0, "unexercisedValue": 532519}, {"maxAge": 1, "name": "Mr. Charles S. Berkman J.D.", "age": 54, "title": "Chief Legal Officer & Secretary", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 711913, "exercisedValue": 0, "unexercisedValue": 207546}, {"maxAge": 1, "name": "Ms. Cia  McCaffrey", "title": "Vice President of People & Talent", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bill  Harriman Ph.D.", "title": "Senior Vice President of Antibody Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Marie-Cecile  van de Lavoir D.V.M., Ph.D.", "title": "Senior Vice President of Technical Operations & Genetics", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christel  Iffland Ph.D.", "title": "Senior Vice President of Antibody Technologies", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Douglas S. Krafte Ph.D.", "age": 65, "title": "Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Donna  Ventura C.P.A.", "title": "Senior VP & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.79, "open": 3.77, "dayLow": 3.745, "dayHigh": 4.01, "regularMarketPreviousClose": 3.79, "regularMarketOpen": 3.77, "regularMarketDayLow": 3.745, "regularMarketDayHigh": 4.01, "forwardPE": -9.238096, "volume": 1382199, "regularMarketVolume": 1382199, "averageVolume": 601787, "averageVolume10days": 789000, "averageDailyVolume10Day": 789000, "bid": 3.86, "ask": 3.92, "bidSize": 200, "askSize": 100, "marketCap": 456346208, "fiftyTwoWeekLow": 3.745, "fiftyTwoWeekHigh": 6.715, "priceToSalesTrailing12Months": 21.683275, "fiftyDayAverage": 4.4338, "twoHundredDayAverage": 5.09165, "currency": "USD", "enterpriseValue": 412274976, "floatShares": 95744865, "sharesOutstanding": 117615000, "sharesShort": 5651415, "sharesShortPriorMonth": 5805792, "sharesShortPreviousMonthDate": 1714435200, "dateShortInterest": 1717113600, "sharesPercentSharesOut": 0.0481, "heldPercentInsiders": 0.05939, "heldPercentInstitutions": 0.74082, "shortRatio": 9.82, "shortPercentOfFloat": 0.0674, "impliedSharesOutstanding": 117615000, "bookValue": 2.567, "priceToBook": 1.5114921, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -63480000, "trailingEps": -0.64, "forwardEps": -0.42, "enterpriseToRevenue": 19.589, "enterpriseToEbitda": -6.468, "52WeekChange": -0.21457487, "SandP52WeekChange": 0.24598539, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "OABI", "underlyingSymbol": "OABI", "shortName": "OmniAb, Inc.", "longName": "OmniAb, Inc.", "firstTradeDateEpochUtc": 1633008600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d14c9ca6-0744-365b-9ae8-349bf02bcf56", "messageBoardId": "finmb_1765536061", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.88, "targetHighPrice": 12.0, "targetLowPrice": 7.0, "targetMeanPrice": 9.88, "targetMedianPrice": 10.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 69007000, "totalCashPerShare": 0.587, "ebitda": -63741000, "totalDebt": 24934000, "quickRatio": 4.17, "currentRatio": 4.379, "totalRevenue": 21046000, "debtToEquity": 8.273, "revenuePerShare": 0.21, "returnOnAssets": -0.13605, "returnOnEquity": -0.19770001, "freeCashflow": -15836000, "operatingCashflow": -42373000, "revenueGrowth": -0.775, "grossMargins": 1.0, "operatingMargins": -5.9334397, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-27"}]